Michael Ehlers. Limelight Bio
December 5, 2019 08:30 AM ESTUpdated 08:51 AM
R&D

Michael Ehlers teas­es plan to build the next 'sig­na­ture' ge­net­ic med­i­cine com­pa­ny with $75M from Ap­ple Tree Part­ners

Amber Tong

When Michael Ehlers jumped ship at Bio­gen to be­come a ven­ture part­ner and CSO at Ap­ple Tree, he al­so got a new job as …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Aca­dia snaps up an es­sen­tial tremor drug af­ter field­'s sum­mer set­backs

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

A service from the Financial Times